Novartis India
NOVARTIND • Pharmaceuticals & Biotechnology
Last Price
₹2082.20
Market Cap
₹5.14K Cr
Sector
Pharmaceuticals & Biotechnology
For educational/research use only. Not a recommendation to buy or sell.
At a glance
as of 2026-09-17Sector: Novartis India (NOVARTIND) is an NSE-listed company in the Pharmaceuticals & Biotechnology sector, within the Pharmaceuticals industry.
Sharia screening: Novartis India is rated Not halal by the specialist provider whose screen we publish.
Price trend
No reading
We don't have enough data to measure this for Novartis India right now.
Institutional activity
Neutral
Trading patterns over recent weeks show no clear sign of institutions buying or selling Novartis India (buying score 2/10, selling score 3/10).
Model rank
Strongly negative
Our model's 5-day return score puts Novartis India ahead of only 18% of NSE stocks. The model is only moderately confident (64%).
Ease of trading
Low
Shares change hands easily; there are no signs of trading drying up (risk score 2/10).
Price vs profits
Well above typical
The share price is 63× last year's profit per share — well above the typical range for NSE stocks (15–30×).
The wider Indian market is in a downtrend (model 100% sure). This affects every stock's model rank.
Browse ready-made screens →Company Information
About Novartis India (NOVARTIND)
Novartis India is an NSE-listed company operating in the Pharmaceuticals & Biotechnology sector, within the Pharmaceuticals industry (ISIN INE234A01025). This page brings together the quantitative research signals our models compute for NOVARTIND: a model-estimated 1-day, 5-day and 21-day return outlook, momentum and trend indicators, institutional-activity context derived from observed trading flows, a snapshot of valuation and quality fundamentals, and the instrument's Sharia-compliance status. All figures are produced by statistical models from historical data and are intended for research and educational purposes.
To read the page, treat the model-estimated return outlook as a relative ranking signal rather than a forecast of price — higher scores reflect stronger model-estimated momentum and trend alignment, not a target or guarantee. The momentum and trend indicators describe how Novartis India's recent price action compares with its own history, while the fundamentals and institutional-activity context add longer-horizon and flow-based perspective. Nothing here is investment advice, a recommendation, or a solicitation to transact; always do your own research and consult a SEBI-registered adviser before making any decision.
The "typical range" we compare a price-to-earnings multiple against is a fixed band for all NSE stocks, not a sector-specific one. Everything on this page describes what our models measured; none of it is a recommendation to do anything.